ClinicalTrials.gg
RecruitingNCT07575984Updated May 13, 2026

Mexidol® Safety and Efficacy in Treatment of Hyperacute and Acute Ischemic Stroke

A Phase 4 interventional study of Mexidol and Glycine in Ischemic Stroke, sponsored by Pharmasoft. Recruiting at 9 sites in Russia. Open to participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-13.

Sponsored by Pharmasoft · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Nov 2025, registered May 2026).
  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Ischemic Stroke with a site in Russia — 12 open to participants now, 12 under way, 2 of them phase 3. Ischemic Stroke · Russia.

Started
2025
with 2 others
Phase 4
2 of 15
2 open now
Primary completion
2027-04
later than 6 of 11 live
Registered
12th of 15
by date
Lead sponsor
2 of 15
Pharmasoft

Among the 15 studies in Ischemic Stroke with a site in Russia, this one is one of 3 that started in 2025, is one of 2 in phase 4, reaches primary completion later than 6 of the 11 other live ones, and was the 12th registered.

Ischemic Stroke

2,619 studies on the registry are indexed under Ischemic Stroke; 978 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

12 of the 15 studies in Ischemic Stroke with a site in Russia are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Russia have not opened yet or have stopped. Only those recruiting at a site in Russia →

Who these studies take

Of the 662 Ischemic Stroke studies recruiting now, 396 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 26 take children under 18; 42 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Ischemic Stroke with a site in Russia, or all of them as a file.
02

Study summary

The primary objective of this study is to further define the mechanisms of action of Mexidol® (solution for intravenous and intramuscular injection, 50 mg/ml) and Mexidol® FORTE 250 (film-coated tablets, 250 mg) in the hyperacute and acute periods of ischemic stroke, and to evaluate their impact on clinical and neuroimaging outcomes of the disease.

Read the detailed description

This is a pilot, randomized, multicenter, comparative, open-label study designed to evaluate the clinical, laboratory, and instrumental efficacy and safety of sequential Mexidol® therapy in patients during the hyperacute and acute periods of ischemic stroke. The study will include 100 patients with acute ischemic stroke and 20 healthy volunteers to establish baseline biomarker values. Patients with ischemic stroke will be randomized in a 1:1 ratio to one of two treatment arms. Group 1 (Experimental) will receive Mexidol® solution (500 mg twice daily, IV drip) for the first 10 days, followed by Mexidol® FORTE 250 tablets (250 mg three times daily) for 60 days. This therapy is administered on top of standard background treatment. Group 2 (Active Comparator) will receive Glycine sublingual tablets (1 g daily) for 5 days on top of standard background treatment. A separate non-randomized healthy volunteer reference group will be enrolled for assessment of normal biomarker levels and will not receive study treatment.

03

Conditions studied

  • Ischemic Stroke

Keywords

  • Ischemic Stroke
  • Hyperacute Stroke
  • Acute Stroke
  • Cerebral Stroke
  • Acute Cerebrovascular Accident
  • ACVA
  • Acute cerebral failure
  • Cerebral Infarction
  • Neuroprotection
  • Mexidol
  • Ethylmethylhydroxypyridine Succinate
  • Antioxidants
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria for Patients:

  1. Signed and dated Form (ICF) by the patient or their legal representative (in case of physical inability to sign), and/or a Decision of the Medical Board.
  2. Men and women aged 18 to 90 years (inclusive) at the time of signing the ICF or Decision of the Medical Board.
  3. First-ever hemispheric ischemic stroke (ICD-10 codes: I63.0-I63.9), confirmed by neuroimaging (CT or MRI).
  4. Presence of occlusion in the internal carotid artery (ICA) system at any level, including the middle cerebral artery (MCA) and anterior cerebral artery (ACA) (anterior circulation) and/or presence of neuroimaging signs, characteristic of acute cerebral ischemia (based on CT perfusion and/or MRI data in accordance with current Clinical Guidelines). Note: Presence of internal carotid artery (ICA) occlusion is not a mandatory criterion; neuroimaging signs of acute cerebral ischemia (CT perfusion/MRI) are sufficient for inclusion.
  5. Time from the onset of acute ischemic stroke symptoms or the time the patient was last known to be well (last known well, LKW) to randomization is no more than 36 hours.
  6. No significant pre-stroke disability (the patient is able to carry out all daily activities and duties without assistance, a score of 0-1 on the modified Rankin Scale (mRS)).
  7. Total National Institutes of Health Stroke Scale (NIHSS) score of 6 to 20 (inclusive) at screening, provided that the score for item 5a/b (Motor Arm: Left/Right) is at least 2 points on the paretic side and/or item 6a/b (Motor Leg: Left/Right) is at least 2 points on the paretic side.
  8. 8. Agreement to use highly effective methods of throughout the study and for 3 weeks after study completion. Eligible participants include: women of , who must have a negative pregnancy test and agree to use the following contraceptive methods: a barrier method (condom or occlusive cap [diaphragm or cervical/vault cap]) or a double-barrier method (condom or occlusive cap [diaphragm or cervical/vault cap] plus spermicide [foam/gel/film/cream/suppository]); women of non-childbearing potential with documented history of hysterectomy, tubal ligation, infertility, or status (at least 1 year of amenorrhea); fertile men who must agree to use barrier contraception; men with documented infertility or prior vasectomy.

Inclusion Criteria for Healthy Volunteers:

  1. White male and female participants aged 18 to 45 years inclusive at the time of signing the Informed Consent Form (ICF).
  2. Verified "healthy" status based on standard clinical, laboratory, and instrumental examination methods.
  3. Ability to provide written informed consent prior to any screening procedures, and the ability, in the investigator's opinion, to comply with all study protocol requirements.
  4. Hemodynamic parameters: systolic blood pressure (SBP) within 100-130 mmHg, diastolic blood pressure (DBP) within 60-90 mmHg, heart rate (HR) 60-90 bpm, and respiratory rate (RR) 16-20 breaths per minute.
  5. (BMI) from 18.5 to 30 kg/m² inclusive.
  6. Willingness to abstain from alcohol throughout the entire study period.
  7. Agreement to use highly effective methods of contraception throughout the entire study. Eligible participants include:

women of childbearing potential, who must have a negative pregnancy test and agree to use the following contraceptive methods: a barrier method (condom or occlusive cap [diaphragm or cervical/vault cap]) or a double-barrier method (condom or occlusive cap [diaphragm or cervical/vault cap] plus spermicide [foam/gel/film/cream/suppository]); women of non-childbearing potential with documented history of hysterectomy, tubal ligation, infertility, or postmenopausal status (at least 1 year of amenorrhea); fertile men who must agree to use barrier contraception; men with documented infertility or prior vasectomy.

Exclusion Criteria for Patients:

  1. to ethylmethylhydroxypyridine succinate or any other components of the product.
  2. Galactose intolerance, lactase deficiency, or glucose-galactose malabsorption.
  3. Inability to take oral medications.
  4. or inability to undergo CT/MRI procedures (including, but not limited to: permanent cardiac pacemakers/neurostimulators; inner ear prosthesis, ferromagnetic or electronic middle ear implants, hemostatic clips, cardiac valve prostheses, or any other metal-containing structures; ferromagnetic fragments; insulin pumps; severe claustrophobia).
  5. Inability to undergo contrast-enhanced imaging for any reason.
  6. Patients who have received or are scheduled to receive thrombolytic therapy or thrombectomy for the current episode of ischemic stroke.
  7. Recurrent ischemic stroke.
  8. Direct signs of irreversible total occlusion of the internal carotid artery (ICA) system at the relevant level within the current episode of ischemic stroke (based on CT/MRI data).
  9. Absence of neuroimaging signs of acute ischemic brain injury.
  10. Presence of any of the following neuroimaging (CT/MRI) findings:

    • Intracranial hemorrhage;
    • Hemorrhagic transformation of the cerebral infarction;
    • Subarachnoid hemorrhage;
    • Brain tumor;
    • Arteriovenous malformation (AVM);
    • Brain abscess;
    • Cerebral aneurysm;
    • Edema of the infarct zone leading to brain structure displacement (malignant cerebral infarction).
  11. Lesion in the vertebrobasilar system.
  12. Any suspicion of subarachnoid hemorrhage (SAH) in the medical history or at the time of screening.
  13. History of hemorrhagic stroke or stroke of unspecified nature.
  14. Any known history of conditions associated with a bleeding tendency.
  15. Deep vein thrombosis (DVT) or pulmonary embolism (PE), or detection of a floating thrombus.
  16. Traumatic brain injury (TBI) within 6 months prior to screening.
  17. History of brain or spinal cord surgery within 5 years prior to study enrollment.
  18. Need for surgical intervention during participation in the clinical study.
  19. History of epilepsy.
  20. History of severe cognitive impairment, including dementia.
  21. Parkinson's disease.
  22. History of hereditary degenerative diseases of the Central Nervous System (CNS).
  23. History of demyelinating diseases of the nervous system.
  24. History of severe or global aphasia and/or clinical evidence of these conditions at screening.
  25. Myocardial infarction within 3 months prior to screening.
  26. Class III-IV chronic heart failure at the time of screening.
  27. Unstable angina pectoris at the time of screening.
  28. SBP ≥ 200 mmHg and/or DBP ≥ 100 mmHg at the time of screening.
  29. History of Stage III-IV (COPD).
  30. Uncontrolled diabetes mellitus.
  31. Renal impairment ( \< 50 mL/min calculated by the Cockcroft-Gault formula) at the time of screening.
  32. Hepatic impairment ( and/or ALT ≥ 2 × and/or total ≥ 1.5 × ULN) at the time of screening.
  33. History of , syphilis, , and/or .
  34. Acute infectious diseases (influenza, upper respiratory tract infections, etc.) within 4 weeks prior to screening.
  35. Use of prohibited medications or other drugs that, in the investigator's opinion, may interfere with the study results within 30 days prior to screening, or the anticipated need for such medications during the patient's participation in the study.
  36. Use of medications based on ethylmethylhydroxypyridine succinate for 3 or more consecutive days within 2 weeks prior to randomization.
  37. Systemic diseases or vascular collagenoses requiring prior or current treatment with systemic , cytostatics, or other .
  38. History of malignant neoplasms, except for patients who have been disease-free for the past 5 years, or those with completely cured basal cell carcinoma of the skin, or completely cured carcinoma in situ.
  39. Other severe, decompensated, or unstable medical conditions that, in the investigator's opinion, are life-threatening, adversely affect the patient's prognosis, or preclude safe participation in the study.
  40. of less than 6 months.
  41. Unwillingness or inability of the patient to comply with the study protocol procedures (in the investigator's opinion).
  42. Pregnancy or breastfeeding (for women).
  43. History of alcoholism, drug addiction, or substance abuse and/or presence of these conditions at screening.
  44. History of schizophrenia, schizoaffective disorder, bipolar disorder, or other psychiatric disorders.
  45. Participation in another clinical trial within 3 months prior to study enrollment.
  46. Any other conditions that, in the investigator's opinion, preclude the patient's inclusion in the study.

Exclusion Criteria for Healthy Volunteers:

  1. Acute or chronic diseases of the cardiovascular, bronchopulmonary, endocrine, and nervous systems, including organic central nervous system (CNS) disorders, as well as gastrointestinal (GI), hepatic, renal, and hematological diseases.
  2. Galactose intolerance, lactase deficiency, or glucose-galactose malabsorption.
  3. Any deviations from normal values during laboratory and/or instrumental examinations.
  4. Inability to undergo blood sampling (e.g., due to compromised skin integrity at venipuncture sites).
  5. History of intracranial hemorrhage of any etiology.
  6. Hemophilia or other blood clotting disorders (including hypocoagulation states) and hemorrhagic diatheses.
  7. Active bleeding of any etiology at the time of screening.
  8. Decreased circulating blood volume (due to a salt-free diet, vomiting, or diarrhea).
  9. Blood donation or blood loss (≥ 450 mL of blood or plasma) within 3 months prior to screening.
  10. Any surgical procedures performed within 30 days prior to screening or planned during the study period.
  11. Acute infectious diseases, as well as fungal infections, within 4 weeks prior to the start of screening.
  12. Vaccination planned during the study or administered within 14 days prior to the start of screening.
  13. Regular use of medications, including herbal and homeopathic remedies, vitamins, and/or dietary supplements, within 4 weeks prior to the start of screening.
  14. Alcohol consumption within 72 hours prior to the start of screening.
  15. Use of medications with a significant effect on hemodynamics and/or liver function (e.g., barbiturates, omeprazole, cimetidine, etc.), injectable or oral hormonal contraceptives, subcutaneous hormonal implants, or intrauterine systems within 2 months prior to screening procedures.
  16. Adherence to a specific diet (e.g., vegetarian, vegan, or low-salt diet) within 2 months prior to the start of screening.
  17. Specific lifestyle factors (e.g., night-shift work, extreme physical exertion) within 2 months prior to the start of screening.
  18. History of alcohol consumption exceeding 10 units per week (1 unit is equivalent to 500 mL of beer, 200 mL of wine, or 50 mL of spirits), or a medical history of alcoholism, drug addiction, or substance abuse.
  19. Smoking at the time of the screening visit.
  20. Piercing, tattoos, or permanent makeup performed within 1 month prior to screening or planned during the study.
  21. Mental, physical, or other reasons preventing the volunteer from adequately assessing their behavior and correctly following the Study Protocol requirements.
  22. Inability or unwillingness to comply with required contraceptive measures.
  23. Pregnancy (confirmed by a positive pregnancy test) or breastfeeding at the time of screening25.
  24. Participation in another clinical trial within 3 months prior to the start of screening.
  25. Other reasons that, in the investigator's opinion, preclude the volunteer's participation in this study.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Mexidol Group

    Patients receive Mexidol® solution followed by Mexidol® FORTE 250 tablets on top of standard background therapy.

    Drug: Mexidol

  • Active comparator
    Glycine Group

    Patients receive Glycine sublingual tablets on top of standard background therapy.

    Drug: Glycine

  • No intervention
    Healthy Volunteers

    Healthy subjects included to obtain control baseline values of biomarkers.

Interventions

  • Phase 1 (Days 1-10): Mexidol® solution, 500 mg (10 ml) twice daily (total daily dose 1000 mg) administered via IV infusion in 100-200 ml of 0.9% NaCl solution for 10 days. Infusion rate: 40-60 drops per minute. Phase 2 (Days 11-70): Mexidol® FORTE 250 film-coated tablets, 250 mg three times daily (total daily dose 750 mg) for 60 days. Administered on top of standard background therapy in accordance with the 2024 Clinical Guidelines of the Ministry of Health of the Russian Federation for Ischemic Stroke and TIA.

  • Glycine, 100 mg sublingual tablets, 1 g (10 tablets) daily for 5 days. Administered on top of standard background therapy in accordance with the 2024 Clinical Guidelines of the Ministry of Health of the Russian Federation for Ischemic Stroke and TIA.

06

What researchers measure

Primary outcomes

  1. Infarct Volume at Visit 2 (Day 11)

    Evaluation of the ischemic lesion volume using Diffusion-Weighted Imaging (DWI).

    Time frame: Day 11 (Visit 2).

Secondary outcomes

  1. Change in Infarct Volume from Baseline to Visit 2 (Day 11)

    Assessment of ischemic lesion dynamics measured by Diffusion-Weighted Imaging (DWI).

    Time frame: Baseline (Visit 0) and Day 11 (Visit 2)

  2. Incidence of Symptomatic Hemorrhagic Transformation (sHT) by Visit 2 (Day 11)

    Number of participants with new intracranial hemorrhage associated with any of the following, according to the Heidelberg Criteria: * Increase in NIHSS total score by ≥ 4 compared to the score immediately prior to deterioration; OR * Increase in any single NIHSS subscale score by ≥ 2; OR * Need for intubation, hemicraniectomy, or ventricular drainage; OR * No other clinical explanation for the patient's deterioration.

    Time frame: Up to Day 11 (Visit 2)

  3. Change in laboratory biomarkers (TNF-α, BDNF, NSE, GFAP, MMP-9, Caspase-3, VCAM-1, MBP, fibronectin)

    Evaluation of the dynamics of laboratory markers to clarify the mechanism of action.

    Time frame: Baseline (Visit 0) and Day 11 (Visit 2)

  4. Assessment of coagulation parameters (D-dimer, fibrinogen).

    Evaluation of blood coagulation dynamics

    Time frame: Baseline (Visit 0) and Day 11 (Visit 2)

  5. Metabolomic assessment (lactate, pyruvate, succinate, malate, fumarate, oxoglutarate, ATP, AMP, ADP, MDA, glutamate, GABA, glycine).

    Evaluation of the dynamics of key metabolites and energy metabolism markers

    Time frame: Baseline (Visit 0) and Day 11 (Visit 2)

  6. Mean modified Rankin Scale (mRS) score at Visit 2 (Day 11), Visit 3 (Day 30±2), Visit 4 (Day 70±2), and Visit 5 (Day 90±2).

    The Modified Rankin Scale (mRS) is used to measure the degree of disability in patients who have had a stroke. Possible scores range from 0 (no symptoms at all) to 6 (death) \[6 point scale: min value 0, max value 6, higher scores mean a worse outcome\].

    Time frame: Day 11 (Visit 2), Day 30±2 (Visit 3), Day 70±2 (Visit 4), and Day 90±2 (Visit 5)

  7. Change from baseline (Visit 0) in the total NIHSS score (The National Institutes of Health Stroke Scale) at Visit 2 (Day 11).

    The National Institutes of Health Stroke Scale (NIHSS) is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. Ratings for each item are scored with 3 to 5 grades with 0 as normal, and there is an allowance for untestable items. The individual scores from each item are summed in order to calculate a patient's total NIHSS score. The maximum possible score is 42 (severe stroke), with the minimum score being a 0 (no stroke symptoms) \[43 point scale: min value 0, max value 42, higher scores mean a worse outcome\].

    Time frame: Baseline (Visit 0) and Day 11 (Visit 2)

  8. Mean total NIHSS score at Visit 2 (Day 11).

    The National Institutes of Health Stroke Scale (NIHSS) is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. Ratings for each item are scored with 3 to 5 grades with 0 as normal, and there is an allowance for untestable items. The individual scores from each item are summed in order to calculate a patient's total NIHSS score. The maximum possible score is 42 (severe stroke), with the minimum score being a 0 (no stroke symptoms) \[43 point scale: min value 0, max value 42, higher scores mean a worse outcome\].

    Time frame: Day 11 (Visit 2)

  9. All-cause mortality rate by Visits 2, 3, 4, and 5.

    The proportion of participants with a fatal outcome (all-cause mortality).

    Time frame: Up to Day 11 (Visit 2), Day 30 (Visit 3), Day 70 (Visit 4), and Day 90 (Visit 5).

  10. Assessment of MRI parameters at Visit 2 (Day 11)

    Evaluation of brain structural parameters using Magnetic Resonance Imaging (MRI)

    Time frame: Day 11 (Visit 2)

  11. Assessment of CT parameters at Visit 2 (Day 11)

    Evaluation of brain structural parameters using Computed Tomography (CT)

    Time frame: Day 11 (Visit 2)

  12. Assessment of Safety and Tolerability

    Total number of adverse events (AEs), stratified by severity and frequency; Incidence of adverse drug reactions (ADRs); Incidence of serious adverse events (SAEs) related to the investigational or comparator products; Proportion of participants with at least one reported AE; Proportion of participants who discontinued treatment due to AEs.

    Time frame: From Day 1 (Visit 1) to Day 90 (Visit 5)

07

Study locations

9 of 9 sites recruiting
  • First City Clinical Hospital named after E.E. Volosevich
    Arkhangelsk, 163000, Russia
    Recruiting
    • Nina M. Khasanova, Cand.Med.Sci, MD · Principal investigator
  • Ivanovo Regional Clinical Hospital
    Ivanovo, 153040, Russia
    Recruiting
    • Yulia V. Batueva, Cand.Med.Sci, MD · Principal investigator
  • Regional Clinical Hospital
    Ryazan, 390039, Russia
    Recruiting
    • Vera S. Kotskaya, MD · Principal investigator
  • Hospital for War Veterans
    Saint Petersburg, 193079, Russia
    Recruiting
    • Maria A. Privalova, Cand.Med.Sci, MD · Principal investigator
  • City Hospital № 40 of Kurortny District
    Saint Petersburg, 197706, Russia
    Recruiting
    • Alina S. Agafina, Cand.Med.Sci, MD · Principal investigator
  • Smolensk Regional Clinical Hospital
    Smolensk, 214018, Russia
    Recruiting
    • Anna V. Sinelshchikova, Cand.Med.Sci, MD · Principal investigator
  • Regional Clinical Hospital
    Tver', 170036, Russia
    Recruiting
    • Ksenia V. Khoroshavina, MD · Principal investigator
  • Regional Clinical Hospital
    Yaroslavl, 150062, Russia
    Recruiting
    • Natalya S. Baranova, Dr.Med.Sci., MD · Principal investigator
  • Zhukovskiy Regional Clinical Hospital,
    Zhukovskiy, 140180, Russia
    Recruiting
    • Valentina V. Kuznetsova, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Apr 2027, 17 months after the start.

Of 85 phase 4 interventional studies under Ischemic Stroke, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 41. This study's planned 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2026
First posted
May 8, 2026
StartActual
Nov 4, 2025
Primary completionEst.
Apr 2027
CompletionEst.
Apr 2027
Last update
May 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07575984
Lead sponsor
Pharmasoft
Responsible party
Sponsor
First posted
May 8, 2026
Start date
Nov 4, 2025
Primary completion
Apr 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
May 13, 2026

Study contacts

Yuriy E. Meshcherskiy, Medical Director, LLC "RPC "PHARMASOFT", Medical Director
Contact
pharmasoft@pharmasoft.ru
007 (495) 626-47-55 ext. 140

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Emoxypine succinate

Start the discussion